As of June 20, 2025, Affimed NV (AFMD) reports a Current Ratio of 3.25.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Affimed NV's Current Ratio
Over recent years, Affimed NV's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2023-12-31 | 3.25 |
| 2022-12-31 | 5.66 |
| 2021-12-31 | 3.20 |
| 2020-12-31 | 2.25 |
| 2019-12-31 | 3.01 |
This slight downward trend highlights how Affimed NV manages its short-term assets and liabilities over time.
Comparing Affimed NV's Current Ratio to Peers
To better understand Affimed NV's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Affimed NV (AFMD) | 3.25 |
| ESSA Pharma Inc (EPIX) | 38.79 |
| Akero Therapeutics Inc (AKRO) | 19.38 |
| Dyne Therapeutics Inc (DYN) | 15.60 |
| Iteos Therapeutics Inc (ITOS) | 12.75 |
| Dynavax Technologies Corp (DVAX) | 10.80 |
Compared to its competitors, Affimed NV's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.